Get all premium features to the best stock analysis tool

Finranks

Company

About us

Contact us

[email protected]

Follow us

Instagram
Telegram
LinkedIn

All rights reserved.

Privacy Policy Terms of Conditions

Home
Markets
Screener
News
About

NPCE - NeuroPace, Inc. Latest News | Finranks

Home

NPCE

(NPCE)

NGM – Real Time Price. Currency in USD

13.33

-0.33 (-2.42%)

At close: Mar 27, 2026, 4:00 PM EDT

13.33

0.00 (0.00%)

After-hours: Mar 27, 2026, 4:10 PM EDT

Summary
News
Chart
Financial
Dividends
Forecast
Ownership
Profile

NPCE RNS System Explained: Growth Drivers and Setup for 2026

NPCE RNS System Explained: Growth Drivers and Setup for 2026

NPCE enters 2026 with rising RNS adoption, stronger margins and Medicare payment hikes that could boost hospital economics for replacement procedures.

Key Catalysts That Will Likely Drive Prospects for NPCE Stock in 2026

Key Catalysts That Will Likely Drive Prospects for NPCE Stock in 2026

NPCE heads into 2026 with 20%+ RNS growth targets, higher Medicare reimbursement and a cleaner revenue mix as the DIXI distribution business rolls off.

NeuroPace's Seizure ID and New Indication Could Expand RNS Demand

NeuroPace's Seizure ID and New Indication Could Expand RNS Demand

NPCE's Seizure ID AI tool and potential idiopathic generalized epilepsy approval could expand RNS adoption as NeuroPace pushes software-driven care in 2026.

NeuroPace to Present at the Leerink Global Healthcare Conference

NeuroPace to Present at the Leerink Global Healthcare Conference

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that its management team will present at the Leerink 2026 Global Healthcare Conference at 8:40am PT on Wednesday, March 11, 2026, in Miami, FL. Management will also host investor meetings during the conference. The presentation will be accessible via live webcast here. A webcast replay will be available for thirty days.

Why NeuroPace Stock Was Inching Higher on Wednesday

Why NeuroPace Stock Was Inching Higher on Wednesday

The niche medical devices specialist published its latest quarterly and annual fundamentals. Led by its No.

NeuroPace, Inc. (NPCE) Q4 2025 Earnings Call Transcript

NeuroPace, Inc. (NPCE) Q4 2025 Earnings Call Transcript

NeuroPace, Inc. (NPCE) Q4 2025 Earnings Call Transcript

NeuroPace, Inc. (NPCE) Reports Q4 Loss, Beats Revenue Estimates

NeuroPace, Inc. (NPCE) Reports Q4 Loss, Beats Revenue Estimates

NeuroPace, Inc. (NPCE) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to a loss of $0.18 per share a year ago.

Videos

No Data

There is no data to display

Press releases

NeuroPace Reports Fourth Quarter and Full Year 2025 Financial Results and Reiterates 2026 Outlook

NeuroPace Reports Fourth Quarter and Full Year 2025 Financial Results and Reiterates 2026 Outlook

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided a corporate update. Fourth Quarter 2025 Financial Highlights Total revenue of $26.6 million, representing growth of 24% compared to the fourth quarter of 2024 RNS System revenue of $22.4 million, representing growth of 26% compa.

NeuroPace Reports Preliminary Unaudited Results for the Fourth Quarter and Fiscal Year 2025 and Initial 2026 Outlook

NeuroPace Reports Preliminary Unaudited Results for the Fourth Quarter and Fiscal Year 2025 and Initial 2026 Outlook

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today reported preliminary unaudited results for the fourth quarter ended December 31, 2025 with total revenue of approximately $26.6 million, an increase of 24% over the fourth quarter of 2024. RNS revenue is expected to be approximately $22.4 million, representing growth of 26% over the fourth quarter of 2024. Cash equivalents and s.

NeuroPace Files PMA Supplement to FDA Seeking Expanded RNS® System Indication for Idiopathic Generalized Epilepsy

NeuroPace Files PMA Supplement to FDA Seeking Expanded RNS® System Indication for Idiopathic Generalized Epilepsy

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that it has filed a Premarket Approval Supplement (PMA-S) application to the U.S. Food and Drug Administration (FDA) seeking to expand the labeled indication for its RNS® System to include patients with antiseizure-medication (ASM) resistant idiopathic generalized epilepsy (IGE) with generalized tonic-clonic seizures.

NeuroPace Announces Positive 18-Month NAUTILUS Trial Results in Idiopathic Generalized Epilepsy

NeuroPace Announces Positive 18-Month NAUTILUS Trial Results in Idiopathic Generalized Epilepsy

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, announced the presentation at the American Epilepsy Society (AES) meeting of preliminary 18-month safety and effectiveness results from its ongoing NAUTILUS1 trial evaluating the RNS® System as an adjunctive therapy for the treatment of antiseizure medication (ASM) resistant idiopathic generalized epilepsy (IGE) with generalized tonic.